Considering the advantage of bispecific antibodies in redirecting immune effector cells to the vicinity of tumor cells, a bispecific antibody AP203 was developed to block tumor PD-L1-medicated immunosuppression and simultaneously activate redirected effector T cells. This evidence concerns the gene CD274 and neoplasm.